Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Detirelix Acetate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR known ✓ | P30968 | 7/20 | 0.70 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.65 |
| ▸ | DRD1 | P21728 | 1/20 | 0.64 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.64 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.64 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.56 |
| ▸ | NMUR2 | Q9GZQ4 | 4/20 | 0.55 |
| ▸ | NMUR1 | Q9HB89 | 4/20 | 0.55 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.55 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Detirelix Acetate SCHEMBL29406059 | 0.99 | GNRHR (0.68) | GNRHRABCB11DRD1OPRM1MRGPRX2 | |
| Detirelix Acetate SCHEMBL29893517 | 0.99 | GNRHR (0.68) | GNRHRABCB11DRD1OPRM1MRGPRX2 | |
| Detirelix Acetate SCHEMBL422026 | 0.99 | GNRHR (0.68) | GNRHRABCB11DRD1OPRM1MRGPRX2 | |
| Acetic Acid SCHEMBL719624 | 0.96 | GNRHR (0.64) | GNRHRABCB11DRD1OPRM1MRGPRX2 | |
| Detirelix Acetate SCHEMBL32670260 | 0.95 | GNRHR (0.74) | GNRHRABCB11DRD1OPRM1MRGPRX2 | |
| Detirelix Acetate SCHEMBL722712 | 0.95 | GNRHR (0.74) | GNRHRABCB11DRD1OPRM1MRGPRX2 | |
| SCHEMBL11099432 | 0.89 | KISS1R (0.63) | GNRHRABCB11DRD1OPRM1MRGPRX2 | |
| SCHEMBL11207519 | 0.87 | GNRHR (0.61) | GNRHRABCB11DRD1OPRM1MRGPRX2 | |
| Ganirelix SCHEMBL29390389 | 0.86 | GNRHR (0.89) | GNRHRABCB11DRD1OPRM1MRGPRX2 | |
| Ganirelix SCHEMBL13625244 | 0.86 | GNRHR (0.89) | GNRHRABCB11DRD1OPRM1MRGPRX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20030125528-A1 | Process for preparing schiff base adducts of amines with o-hydroxy aldehydes and compositions of matter based thereon | HAY BRUCE A (US) | 2003-07-03 | — | — | US | claimed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12465564-B2 | Oral and nasal compositions and methods of treatment | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250339367-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-12403090-B2 | Oral film compositions and dosage forms having precise active dissolution profiles | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250255780-A1 | SYSTEM AND METHOD FOR MAKING PERSONALIZED INDIVIDUAL UNIT DOSES CONTAINING PHARMACEUTICAL ACTIVES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-08-14 | — | — | US | disclosed |
| US-12310922-B2 | System and method for making personalized individual unit doses containing pharmaceutical actives | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20010002404-A1 | Fatty acid-pharmaceutical agent conjugates | LUITPOLD PHARMACEUTICALS, INC. | 2001-05-31 | — | — | US | disclosed |
| EP-1087989-A1 | IMPROVED PROCESS FOR PREPARING SCHIFF BASE ADDUCTS OF AMINES WITH O-HYDROXY ALDEHYDES AND COMPOSITIONS OF MATTER BASED THEREON | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-2000000507-A1 | IMPROVED PROCESS FOR PREPARING SCHIFF BASE ADDUCTS OF AMINES WITH O-HYDROXY ALDEHYDES AND COMPOSITIONS OF MATTER BASED THEREON | PFIZER PRODUCTS INC. (US) | 2000-01-06 | — | — | WO | disclosed |
| WO-1999030690-A1 | ORAL DELIVERY FORMULATION | AXIA THERAPEUTICS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| EP-0909183-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | Neuromedica, Inc. (US) | 1999-04-21 | — | — | EP | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| WO-1997044063-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | NEUROMEDICA, INC. (US) | 1997-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125528-A1 | Process for preparing schiff base adducts of amines with o-hydroxy aldehydes and compositions of matter based thereon | OGDH, ALDH7A1, AOX1 | GNRHR 4880/4885ABCB11 4836/4885DRD1 2500/4885 |
| US-20010002404-A1 | Fatty acid-pharmaceutical agent conjugates | FABP7, FFAR2, FFAR4 | GNRHR 1851/4885ABCB11 592/4885DRD1 2497/4885 |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | GNRHR 2387/4885ABCB11 1727/4885DRD1 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.